Aclarion, Inc. announced its participation in the 38th Annual ROTH Conference from March 22-24, 2026, where CEO Brent Ness will meet with institutional investors and analysts to discuss the company's progress and future catalysts. The commercial-stage healthcare technology company, which trades on Nasdaq under symbols ACON and ACONW, will highlight its Nociscan platform—a proprietary MR spectroscopy system designed to help physicians identify painful discs in patients with chronic low back pain.
This announcement matters because chronic low back pain represents a substantial healthcare burden, affecting millions globally and often leading to invasive procedures when pain sources remain unclear. Aclarion's technology addresses this diagnostic gap by using biomarkers and augmented intelligence algorithms to noninvasively distinguish between painful and nonpainful discs. The company's participation in a major investment conference signals its transition from development to commercialization phase, with implications for both healthcare delivery and medical technology investment.
During the conference, Ness will emphasize Aclarion's strong balance sheet and debt-free position as enabling factors for executing its expansion strategy in both the United Kingdom and United States markets. The company's cloud-based SaaS platform receives magnetic resonance spectroscopy data from MRI machines, processes it using proprietary techniques to extract pain-associated biomarkers, and applies algorithms to indicate potential pain sources. This approach provides physicians with additional diagnostic clarity when combined with other assessment tools.
The potential impact extends beyond immediate clinical applications to broader healthcare economics. More precise diagnosis could reduce unnecessary procedures, improve treatment outcomes, and lower overall healthcare costs associated with chronic back pain management. For investors, the company's progress represents an opportunity in the growing digital health and diagnostic AI sectors, particularly as Aclarion advances toward key 2026 milestones.
Readers can find additional company information at https://www.aclarion.com, while the latest updates relating to Aclarion are available at https://tinyurl.com/aconnewsroom. The company's technology represents a convergence of medical imaging, biomarker science, and artificial intelligence—three areas experiencing rapid innovation in healthcare. As Aclarion seeks to expand adoption of Nociscan, its conference participation serves as both a business development opportunity and a marker of the evolving landscape for pain diagnosis technologies.
